SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced expansion of optical genome mapping (OGM) based testing of hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK), following approval from the New York State Department of Health (NYSDOH).
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
